Overview
At Immunovive, we strive to make a difference in the world of immunotherapeutics. Our mission is to accelerate life science research and biologics discovery by providing a premium antibody discovery service rapidly and affordably. Our BinderGenᵀᴹ HTP hybridoma platform generates diverse high-affinity monoclonal antibody binders in 6-8 weeks enabling discovery of critical reagents, therapeutic leads, and substrates for the development of multimodalities. Decades of leadership, expertise, and innovation is applied to each and every project culminating in an optimized research plan designed to deliver high-quality monoclonal antibodies at industry-leading timelines. All operations are conveniently located in the Greater Boston area and our clients retain full ownership of antibodies that we discover together.